Illumina, Inc. $ILMN Shares Purchased by Jupiter Asset Management Ltd.

Jupiter Asset Management Ltd. increased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 54.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 271,354 shares of the life sciences company’s stock after acquiring an additional 95,594 shares during the quarter. Jupiter Asset Management Ltd.’s holdings in Illumina were worth $35,591,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in the business. Capital World Investors grew its position in shares of Illumina by 20.0% during the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after buying an additional 3,331,542 shares in the last quarter. State Street Corp grew its holdings in Illumina by 6.8% during the 3rd quarter. State Street Corp now owns 5,999,790 shares of the life sciences company’s stock worth $569,800,000 after acquiring an additional 382,520 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Illumina by 3.1% in the 3rd quarter. AQR Capital Management LLC now owns 3,398,027 shares of the life sciences company’s stock worth $315,915,000 after purchasing an additional 102,147 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Illumina by 4.8% in the 4th quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock worth $375,260,000 after purchasing an additional 130,139 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in shares of Illumina by 1.9% in the 2nd quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock valued at $184,222,000 after purchasing an additional 35,167 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Stock Up 5.7%

Shares of Illumina stock opened at $158.70 on Friday. The stock has a market capitalization of $24.01 billion, a price-to-earnings ratio of 28.85, a PEG ratio of 2.49 and a beta of 1.42. Illumina, Inc. has a twelve month low of $78.79 and a twelve month high of $158.79. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The business’s 50 day simple moving average is $132.92 and its 200-day simple moving average is $131.80.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm’s revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities research analysts forecast that Illumina, Inc. will post 5.2 earnings per share for the current year.

Insider Activity

In other news, SVP Christensen Jakob Wedel sold 700 shares of Illumina stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total transaction of $97,328.00. Following the sale, the senior vice president owned 15,056 shares of the company’s stock, valued at approximately $2,093,386.24. The trade was a 4.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 104,393 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $145.34, for a total value of $15,172,478.62. Following the transaction, the director owned 3,500,048 shares of the company’s stock, valued at approximately $508,696,976.32. This represents a 2.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 330,160 shares of company stock worth $48,028,308. 2.90% of the stock is currently owned by insiders.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina and SPT Labtech launched fireflyGO, a new automation platform designed to make targeted oncology research faster, simpler, and more scalable. The product is integrated with Illumina’s MiSeq i100 Series and could help broaden adoption of its sequencing workflow. Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
• Positive Sentiment: Illumina also introduced a distributed whole-genome sequencing solution for MRD research, expanding its oncology portfolio and making it easier for more labs to adopt molecular residual disease testing in clinical research. That supports the company’s long-term growth narrative in precision oncology. Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
• Neutral Sentiment: A separate marketwide report noted that the broader stock market reached fresh highs on upbeat macro news. While this may be helping overall sentiment, it is not specific to Illumina’s business. Dow Jones Futures: Stock Market Hits Highs On U.S.-Iran Deal; Dell Surges On Earnings
• Neutral Sentiment: One article flagged Illumina as a strong momentum stock, which may reinforce positive trader sentiment, but it did not include new fundamental information. Here’s Why Illumina (ILMN) is a Strong Momentum Stock

Analysts Set New Price Targets

Several equities analysts have recently commented on ILMN shares. Evercore reaffirmed an “outperform” rating on shares of Illumina in a research report on Friday, May 1st. UBS Group reaffirmed a “neutral” rating and set a $135.00 target price on shares of Illumina in a report on Friday, February 6th. Barclays boosted their price target on Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a report on Friday, May 1st. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective for the company in a report on Thursday, May 14th. Finally, Citigroup increased their target price on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a report on Monday, May 4th. Seven investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $137.75.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.